“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Catalyst Pharmaceuticals


Catalyst Pharmaceuticals products


Agamree®

  • Generic: vamorolone (oral suspension)

  • Indication: treatment of Duchenne muscular dystrophy (patients aged 2 years and older)

  • Usage: once-daily oral suspension as prescribed

Firdapse®

  • Generic: amifampridine phosphate (tablets)

  • Indication: Lambert–Eaton myasthenic syndrome (LEMS) in adults and children (≥ 6 years)

  • Usage: oral tablets; dosing individualized—recently approved expanded max daily dose of up to 100 mg

Fycompa®

  • Generic: perampanel (controlled substance CIII)

  • Indication: epilepsy (partial-onset seizures, with or without generalization)

  • Usage: once-daily oral dosing as per seizure control and tolerability



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)